The impact of DPP-4 inhibitor on daily glucose profile and coronary plaque character in diabetic patients with coronary artery disease

The impact of DPP-4 inhibitor on daily glucose profile and coronary plaque character in diabetic patients with coronary artery disease - the IMpact of sitAgliptin on daily Glucose profIle and coroNary plaquE character in diabetic patients with coronary artery disease:IMAGINE-KOBE study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008344

Enrollment

Registered

2012-07-04

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with coronary artery disease and type 2 diabetes

Interventions

Sitagliptin group:start with Sitagliptin 50 mg/day and up to 100 mg/day Metformin group:Metformin 500 mg/day and up to 1000 mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)In patients undergoing PCI, "untreated diabetes" and "HbA1c(NGSP) between 6.5 and 8.4, or FBS > 126mg/dl or casual blood glcose > 200mg/dl" 2)LDL-chol < 100mg/dl in patients without statin. LDL-chol < 120mg/dl in patients with statin. 3)patients between 20 and 75 years old 4)Written consent for participation in the study

Exclusion criteria

Exclusion criteria: Patients meeting one of the following conditions will be excluded: 1) poor control:HbA1c(NGSP)>8.5, or under treatment of diabetes, or type 1 diabetes 2)severe liver dysfunction 3)severe renal dysfunction (Cre 1.3 mg/dL) 4)severe heart failure) (NYHA/New York Heart Association stage III or severer) 5)Malignancies or other diseases with poor prognosis 6) pregnant, lactating, and possibly pregnant women and those planning to become pregnant 7) past medical history of hypersensitivity to investigational drugs 8) judged as ineligible by clinical investigators

Design outcomes

Primary

Measure	Time frame
Change in coronary plaque character analyzed by coronary angiography, intravascular ultrasound, and optical coherence tomography, and daily glucose profile analyzed by 24-hour continuous glucose monitoring system before and after 6 months treatment with sitagliptin in comparison with metformine	—

Countries

Japan

Contacts

Public ContactHiroyuki Yamamoto

Kobe University Graduate School of Medicine Division of Cardiovascular Medicine

y0493589m@hotmail.co.jp+81-78-382-5846

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026